Citius Oncology (CTOR) vs. The Competition Head to Head Contrast

Citius Oncology (NASDAQ:CTOR) is one of 847 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Citius Oncology to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, risk and dividends.

Insider & Institutional Ownership

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Citius Oncology and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Citius Oncology	$7.11 million	N/A	-1.30
Citius Oncology Competitors	$105.26 million	-$42.92 million	-9.94

Citius Oncology’s rivals have higher revenue, but lower earnings than Citius Oncology. Citius Oncology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Citius Oncology and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	N/A	N/A
Citius Oncology Competitors	-14,339.21%	-509.11%	-45.42%

Risk & Volatility

Citius Oncology has a beta of 3.39, suggesting that its share price is 239% more volatile than the S&P 500. Comparatively, Citius Oncology’s rivals have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Citius Oncology and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	0	0	1.00
Citius Oncology Competitors	9766	14998	45296	1578	2.54

As a group, “Biotechnology” companies have a potential upside of 92.38%. Given Citius Oncology’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology has less favorable growth aspects than its rivals.

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.